2019, 2018, 2017, 2016, 2015, 2014, 2013
January – March Net sales amounted to MSEK 793.6 (420.8). This corresponds to an increase of 89% for the period. The organic growth during the first quarter was 27%, currency impact -1% and 63% relates to the acquisition of Trimb in 2019 and the product portfolio acquired from Leo Pharma (see below). EBIT amounted to...
Today, on 1 April 2020, Karo Pharma is publishing its annual report for 2019 on the company’s website, www.karopharma.com. FOR ADDITIONAL INFORMATION, PLEASE CONTACT: Jon Johnsson, CFO, +46 735 078 861, jon.johnsson@karopharma.com ABOUT KARO PHARMA Karo Pharma specialises in the sales and marketing of prescription drugs and over the counter products for everyday healthcare. Karo...
OCTOBER – DECEMBER · Net sales amounted to MSEK 649.3 (463.3). This corresponds to an increase of 40% for the period. The organic growth during the fourth quarter was -4 %, currency impact 2 % and 42 % refers to the acquisition of Trimb. · Adjusted EBITDA* amounted to MSEK 151.4 (165.4) excluding non-recurring items,...
